Rising Prevalence of Chronic & Infectious Diseases
The rising prevalence of chronic and infectious diseases is a key driver propelling the growth of the dried blood spot (DBS) testing market. Chronic diseases, notably cardiovascular diseases and diabetes, represent significant global health burdens. According to World Health Organization (WHO) data, chronic conditions are responsible for approximately 74% of all deaths worldwide, equating to around 41 million deaths annually. Cardiovascular diseases alone account for 17.9 million deaths each year, underscoring their critical impact. The global prevalence of diabetes has surged to approximately 422 million cases, fueling ongoing demand for minimally invasive and accessible monitoring solutions such as DBS.
In the infectious disease sector, the COVID-19 pandemic has fundamentally transformed diagnostic strategies. The Centers for Disease Control and Prevention (CDC) reported that over 925 million COVID-19 tests were processed in the United States alone between March 2020 and December 2021. This unprecedented testing volume accelerated infrastructure development for alternative sampling methods, including DBS, which offers advantages such as ease of collection and transportation, especially in resource-limited settings.
Furthermore, the persistent burden of HIV continues to drive DBS adoption. UNAIDS 2023 data indicates that approximately 39.9 million people worldwide are living with HIV, necessitating regular viral load testing. DBS facilitates simplified, home-based sample collection, improving access and compliance, particularly in regions like sub-Saharan Africa, where 25.6 million individuals are HIV-positive and face healthcare access barriers.
Similarly, hepatitis B and C infections, affecting 296 million and 58 million people respectively (WHO 2024), are significant contributors to market growth. DBS enables efficient seroprevalence studies and ongoing treatment monitoring in remote and underserved populations. The CDC has validated DBS for multiple hepatitis assays, demonstrating a sensitivity of 98.7% for hepatitis C virus RNA detection compared to plasma samples, highlighting its diagnostic accuracy.
In tuberculosis control efforts, with WHO reporting 10.6 million new cases in 2022, DBS offers a vital solution for pediatric diagnosis, where limited blood volume complicates traditional sampling methods. Additionally, epidemiological surveillance of antimicrobial resistance (AMR) is enhanced through DBS, as evidenced by the European Centre for Disease Prevention and Control (ECDC), which incorporates DBS into its AMR monitoring programs across 27 member states, processing over 50,000 samples annually.
Demographic shifts, such as aging populations—Japan's Ministry of Health reports that 29.1% of its population is over 65, with multimorbidity rates exceeding 60%—further amplify the demand for convenient, longitudinal biomarker monitoring solutions like DBS. This need is reflected in the increasing integration of DBS technology into clinical trials; pharmaceutical companies report a 40% growth in DBS-based pharmacokinetic data submissions to regulatory agencies like the FDA between 2020 and 2023, validating its critical role in therapeutic monitoring for chronic conditions.
Therefore, the escalating global burden of both chronic and infectious diseases, driven by demographic shifts, lifestyle factors, and emerging infectious threats, remains the primary factor fueling the expansion of the DBS testing market. This trend underscores the vital role of DBS technology in improving diagnostic accuracy, accessibility, and disease management worldwide.
Increasing Newborn Screening Programs Globally
The global expansion of newborn screening programs is a critical driver fueling the growth of the neonatal diagnostic market. This trend is primarily propelled by the increasing prevalence of inherited metabolic disorders, immunodeficiency syndromes, and other congenital conditions detectable through newborn screening. For instance, in the United States, approximately 4 million newborns are screened annually, leading to the identification of nearly 12,000 treatable conditions each year, including phenylketonuria (PKU), congenital hypothyroidism, cystic fibrosis, and severe combined immunodeficiency (SCID). Early detection of these conditions enables timely intervention, significantly reducing morbidity, mortality, and long-term healthcare costs.
The expansion of screening panels, driven by recommendations from health authorities such as the Advisory Committee on Heritable Disorders in Newborns and Children, has increased the number of conditions screened—from 29 in 2015 to 37 core conditions today—further amplifying market demand. The inclusion of diseases like SCID, which can be effectively detected via T-cell receptor excision circle (TREC) analysis of dried blood spots (DBS), exemplifies technological advancements enhancing screening capabilities.
Developing markets are also rapidly embracing newborn screening initiatives. India’s RBSK program, operating across 730 districts, has screened over 25 million children using DBS methodology, emphasizing its importance in early diagnosis within resource-constrained settings. The World Health Organization (WHO) recommends DBS as the preferred method for universal newborn screening in low-resource environments due to its stability at ambient temperatures for up to 14 days and its safety profile.
Technological advancements, such as tandem mass spectrometry (MS/MS), have significantly increased screening capacity by up to tenfold enabling high-throughput analysis in laboratories worldwide. In the U.S., over 95% of neonatal screening laboratories utilize automated punchers and flow-injection analysis, reducing analytical times to less than two minutes per sample. These innovations are driving increased reagent and consumable demand, further accelerating market growth.
Thus, the global expansion of newborn screening programs fueled by rising disease prevalence, technological progress, and supportive health policies is a key factor propelling the growth of the neonatal diagnostic market. The focus on early detection and intervention for genetic and metabolic disorders underscores the vital role of newborn screening in improving long-term health outcomes worldwide.
Increasing Forensic Toxicology Applications
The increasing application of Forensic Toxicology is a key driver propelling the growth of the market, primarily fueled by the rising prevalence of drug abuse, emerging synthetic psychoactive substances, and chemical exposures. Notably, the World Drug Report 2023 by the United Nations Office on Drugs and Crime (UNODC) estimates that approximately 296 million people worldwide used drugs in the past year, underscoring the urgent need for efficient, large-scale toxicological screening solutions. These developments are further supported by the proliferation of synthetic opioids, such as fentanyl and its analogues, which have been linked to a sharp rise in overdose deaths. For example, the Centers for Disease Control and Prevention (CDC) reports that synthetic opioids contributed to nearly 70% of all drug overdose deaths in 2022, emphasizing the critical role of advanced forensic toxicology techniques.
Forensic toxicology applications, particularly those utilizing dried blood spot (DBS) technology, are instrumental in addressing these challenges. DBS offers minimally invasive sample collection, superior sample stability, and the capacity for high-throughput screening, making it ideal for both clinical and forensic contexts. Validation studies funded by the U.S. National Institute of Justice demonstrate that DBS can successfully detect over 230 drugs of abuse, including fentanyl analogues, with an accuracy range of 94-98% compared to traditional blood matrices—while requiring only 50 µL of blood versus 10 mL for venipuncture.
